Search Within

Martin Henner Voss

Formats
  1. Meeting Abstract (150)
  2. Journal Article (122)
  3. Review (6)
  4. Editorial (5)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (288)
  2. Genitourinary Oncology Service (288)
  3. Solid Tumor Oncology Division (288)
  4. Human Oncology and Pathogenesis Program (104)
  5. Weinberg Fellows (104)
  6. Surgery (103)

More Groups

People
  1. Robert Motzer (176)
  2. Abraham Hakimi (95)
  3. Darren Feldman (80)
  4. Chung-Han Lee (75)
  5. Maria Carlo (65)
  6. Ritesh Kotecha (63)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (24)
  5. 2021 (30)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (116)
  2. Clinical Cancer Research (18)
  3. BJU International (15)
  4. Annals of Oncology (13)
  5. Journal for ImmunoTherapy of Cancer (12)
  6. Clinical Genitourinary Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (120)
  2. American Association for Cancer Research (26)
  3. Wiley Blackwell (22)
  4. Elsevier Inc. (21)
  5. Oxford University Press (18)
  6. Biomed Central Ltd (15)

More Publishers

Results (288)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genome-driven paradigm for the development of selective fibroblast growth factor receptor inhibitors
    Journal Article

    Schram, A. M.; Voss, M. H.; Hyman, D. M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Baseline lactate dehydrogenase (LDH) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with everolimus (EVE) versus sunitinib (SUN): Predictive biomarker analysis from the RECORD-3 trial
    Meeting Abstract

    Voss, M. H.; Chen, D.; Marker, M.; Knox, J.; Hsieh, J.; Voi, M.; Motzer, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)
    Meeting Abstract

    Meric-Bernstam, F.; Tannir, N. M.; Mier, J. W.; DeMichele, A.; Telli, M. L.; Fan, A. C.; Munster, P. N.; Carvajal, R. D.; Orford, K. W.; Bennett, M. K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Medullary renal cell carcinoma (RCC): Genomics and treatment outcomes
    Meeting Abstract

    Carlo, M. I.; Chen, Y.; Chaim, J.; Coskey, D. T.; Woo, K.; Hsieh, J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; Lee, C. H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • CX-839-004: A phase I/II study of the safety, pharmacokinetics, and pharmacodynamics of the glutaminase inhibitor CB-839 combined with nivolumab in patients with renal cell carcinoma, melanoma, and non-small cell lung cancer
    Meeting Abstract

    Lam, E.; Tannir, N. M.; Meric-Bernstam, F.; Vaishampayan, U.; Orford, K. W.; Molineaux, C.; Gross, M.; MacKinnon, A.; Voss, M.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Phase I study of everolimus in combination with gemcitabine and split-dose cisplatin in advanced urothelial carcinoma
    Journal Article

    Abida, W.; Milowsky, M. I.; Ostrovnaya, I.; Gerst, S. R.; Rosenberg, J. E.; Voss, M. H.; Apolo, A. B.; Regazzi, A. M.; McCoy, A. S.; Boyd, M. E.; more...
    Bladder Cancer (2016)

    Fulltext@MSK | Save
  • Updated results from a phase I study of nivolumab (nivo) in combination with ipilimumab (ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
    Meeting Abstract

    Hammers, H.; Plimack, E. R.; Infante, J. R.; Rini, B. I.; McDermott, D.; Lewis, L.; Voss, M. H.; Sharma, P.; Pal, S. K.; Razak, A.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC)
    Meeting Abstract

    Meric-Bernstam, F.; Tannir, N.; Harding, J.; Voss, M.; Mier, J.; DeMichele, A.; Munster, P.; Patel, M.; Iliopoulos, O.; Owonikoko, T.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Updated results from a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 study
    Meeting Abstract

    Hammers, H. J.; Plimack, E. R.; Infante, J. R.; Rini, B. I.; McDermott, D. F.; Lewis, L. D.; Voss, M. H.; Sharma, P.; Pal, S. K.; Razak, A.; more...
    BJU International (2016)

    Fulltext@MSK | Save
  • Differential overall survival results in RECORD-3 study based on three distinct clear cell metastatic renal cell carcinoma molecular subgroups classified by BAP1 and/or PBRM1 mutations
    Meeting Abstract

    Hsieh, J.; Chen, D.; Wang, P.; Chen, Y. B.; Mahtab, M.; Pate, P.; Bhanot, U.; Berger, M.; Cheng, E.; Knox, J.; more...
    BJU International (2016)

    Fulltext@MSK | Save